Ebola virus vaccine - Profectus Biosciences

Drug Profile

Ebola virus vaccine - Profectus Biosciences

Alternative Names: Monovalent vesicular stomatitis virus vectored Ebola virus vaccine - Profectus Biosciences; VesiculoVax™ Zaire-Ebola virus - Profectus Biosciences; VesiculoVax™-vectored Ebola virus vaccine - Profectus Biosciences

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator Profectus Biosciences
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 19 Jan 2016 Phase-I clinical trials in Ebola virus infections (Prevention) in USA (IM)
  • 23 Sep 2011 Preclinical trials in Ebola virus infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top